Skip to main content

Advertisement

Log in

Cholinesterase inhibitors in dementia

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Doody RS, Stevens JC, Beck C, et al.: Practice parameter: management of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1154–1166.

    PubMed  CAS  Google Scholar 

  2. McKeith I, Del Ser T, Spano PE, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo controlled international study. Lancet 2000, 356:2031–2036.

    Article  PubMed  CAS  Google Scholar 

  3. Tariot PN, Solomon PR, Morris JC: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000, 54:2269–2276.

    PubMed  CAS  Google Scholar 

  4. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study group. Neurology 2000, 54:2261–2268.

    PubMed  CAS  Google Scholar 

  5. Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementa. North American Egb Study Group. JAMA 1997, 278:1327–1332.

    Article  PubMed  Google Scholar 

  6. van Dongen MC, van Rossum E, Kessels AG, et al.: The efficacy of gingkgo for elderly people with dmentia an dage-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000, 48:1183–1194.

    PubMed  Google Scholar 

  7. European Pentoxifyline Multi-Infarct Dementia (EPMID) Study Group: European Pentoxyifylline Multi-Infarct Dementia Study. Eur Neruol 1996, 36:315–321.

    Google Scholar 

  8. Black R, Barclay L, Nolan K, et al.: Pentoxifylline in cerebrovascular dmentia. J Am Geriatr Soci 1992, 40:237–244.

    CAS  Google Scholar 

  9. Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon in Alzheimr’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000, 7:159–169.

    Article  PubMed  CAS  Google Scholar 

  10. Ebmeier KP, Calder SA, Crawford JR, et al.: Dementia in idiopathic Parkinson’s disease: prevalence and relationship with symptoms and signs of parkinsonism. Psychol Med 1991, 21:69–76.

    Article  PubMed  CAS  Google Scholar 

  11. Mayeux R, Denaro J, Hemenegildo N, et al.: A populationbased investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992, 49:492–497.

    PubMed  CAS  Google Scholar 

  12. Tison F, Dartigues JF, Auriacombe S, et al.: Dementia in Parkinson’s disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995, 45:705–708.

    PubMed  CAS  Google Scholar 

  13. Marder K, Tang MX, Cote L, Stern Y, Mayeux R: The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 1995, 52:695–701.

    PubMed  CAS  Google Scholar 

  14. Aarsland D, Tandberg E, Larsen JP, Cummings JL: Frequency of dementia in Parkinson disease. Arch Neurol 1996, 53:538–542.

    PubMed  CAS  Google Scholar 

  15. Hurtig HI, Trojanowski JQ, Galvin J, et al.: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000, 54:1916–1921.

    PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marder, K. Cholinesterase inhibitors in dementia. Curr Neurol Neurosci Rep 2, 390–391 (2002). https://doi.org/10.1007/s11910-002-0063-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-002-0063-9

Keywords

Navigation